Earlier this week, the Harvard Law School opened a psychedelics policy center, which it believes will be useful to physicians navigating this growing field as more policies of reform are approved. The Project on Psychedelics Law and Regulation, as the center will be known, has been established to promote equity, innovation and safety in psychedelics therapeutics, commerce and research.
A press release by the Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics at Harvard acknowledges that local and state psychedelics development involves assessments of the effects of policy as well as the possible impact of private companies that seek to enter this burgeoning market.
The project’s director Mason Marks, who also happens to be a senior fellow at the Petrie-Flom Center, stated that only a few psychedelic research centers exist at different learning institutions in the country that center on clinical research, noting that there wasn’t any systematic research being done on psychedelics law. He also asserted that the Project on Psychedelics Law and Regulation, which has been dubbed POPLAR, would help fill the gap.
Marks, who is also a member of the state of Oregon’s psilocybin advisory board, has stated in an interview that the project would also work to address ethical issues that impact physicians who are working with psychedelic substances. He also talked about how federal legislations hindered the research on these substances.
There has been growing academic interest in psychedelic substances as more activists call for an end to the criminalization of substances such as ibogaine, DMT and psilocybin.
Earlier in 2019, the Johns Hopkins University opened the first center in the country that would focus on the research of psychedelic drugs, exclusively. Similarly, POPLAR will also look into psychedelics medical benefits, while also focusing on ethics and law.
Jeannie Suk, a law professor at Harvard, stated that prior research proposed that psychedelics held great benefits for individuals who suffered from PTSD and trauma, noting that by conducting an analysis of political, legal and social barriers to access with regard to the substances, the project could further the understanding of the substances’ possible effect as therapies.
POPLAR is being privately financed by individuals such as Matt Mullenweg, who played a huge role in the development of WordPress and is also the CEO of Automattic, and Tim Ferriss, a philanthropist who will be making his contributions through the Saisei Foundation. Both individuals also financed the Johns Hopkins psychedelic center.
The launch of the center focusing on psychedelics policy at Harvard University is a good complement to the work being done by companies such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) geared at developing psychedelic medicines targeting a number of diseases.
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
